Esperion Therapeutics (ESPR) EBIAT (2018 - 2025)
Historic EBIAT for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$31.3 million.
- Esperion Therapeutics' EBIAT fell 612.72% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 2196.59%. This contributed to the annual value of -$51.7 million for FY2024, which is 7527.1% up from last year.
- Esperion Therapeutics' EBIAT amounted to -$31.3 million in Q3 2025, which was down 612.72% from -$12.7 million recorded in Q2 2025.
- Esperion Therapeutics' EBIAT's 5-year high stood at $61.0 million during Q1 2024, with a 5-year trough of -$90.9 million in Q1 2021.
- Its 5-year average for EBIAT is -$44.6 million, with a median of -$55.1 million in 2022.
- As far as peak fluctuations go, Esperion Therapeutics' EBIAT soared by 19887.07% in 2024, and later plummeted by 16629.58% in 2025.
- Esperion Therapeutics' EBIAT (Quarter) stood at -$65.1 million in 2021, then grew by 14.79% to -$55.5 million in 2022, then decreased by 1.54% to -$56.3 million in 2023, then surged by 62.16% to -$21.3 million in 2024, then tumbled by 46.98% to -$31.3 million in 2025.
- Its EBIAT stands at -$31.3 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$40.5 million for Q1 2025.